Day 2
Location: Room K1
Over the past 30 years, there have been profound changes in life science leadership, driven by factors such as advancing technology and more. This session explores the first-hand experience of the journey, from ‘scientific expertise’ driven leadership to the rise in need for versatile, resilient and forward-thinking leaders, capable of integrating science with business strategy and adapting to rapid technological advancements, to drive innovation in today’s increasingly complex and interconnected industry.
Location: Room K1
Join this session to celebrate 40 years of Mike Ward’s remarkable journey in reporting and analyzing the biotech industry. Over four decades, Mike has contributed to publications including Nature, Financial Times, Scrip and more, and has engaged with countless leaders in the pharma, biotech, and investment communities. As his passion and dedication to understanding and communicating the transformative power of biotech remains strong, hear about his experiences, visions for the industry, his future endeavours in the years to come.
Location: Room K1
Join this session to watch an exclusive recording of the Flot.bio Show, filmed for the first time at an event in collaboration with EBD. Host Philip Hemme chats with Lovisa Afzelius, General Partner at Flagship Pioneering. They will talk about the four biotech companies Lovisa co-founded since joining Flagship in early 2020, Flagship’s European initiatives, and her journey as one of Sweden’s leading female biopharma executives.
Location: Room K2
As the pharma patent cliff approaches, this panel will explore its impact on the industry, examining future pipelines and emerging partnering opportunities. Join industry leaders to discuss strategies for innovation and collaboration, ensuring sustained growth and advancement in the life science landscape. Discover what lies ahead in this pivotal decade.
Location: Room K2
In an era of rapid scientific progression, Immunology has advanced to be the second-largest segment in the biopharma industry, by sales. Join this session to discover the current state of the field, key drivers behind the growth and delve into significant deals, such as the Morphic and DICE by Eli Lilly. Explore the evolving landscape of licensing and partnering opportunities for novel immunological innovations, and gain insights into emerging trends and prospects in the future.
Location: Room K2
Reimagining medicine, together. Working together, we can reimagine medicine to improve and extend people’s lives.
Location: Room K2
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries
Location: Room K2
We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
Location: Room K2
At Lilly, we take smart risks on bold science to achieve our mission of bringing life-changing medicines to patients. As a community of scientists, we understand the brilliance and dedication this work takes. We also recognize our responsibility as partners to help advance life-changing medicines within our walls and beyond. More than 100 years ago, we pioneered strategic collaborations to scale the bold work of four University of Toronto research scientists to launch the world’s first commercial insulin. We're proud to continue our legacy in collaboration, with ~50% of our new product launches in the last 10 years enabled by external innovation, and over 70 active alliances with the vibrant academic and biotech ecosystem. We know that every partnership is different - from stage, modality, therapeutic area, and culture. We have the skill, capabilities, and know-how to bring a holistic suite of models to life to continuously meet your needs. Let’s grow together!
Location: Room K2
We strive to improve the health of humans and animals - for generations. We work together with integrity and are guided by a shared purpose that defines who we are and what we do
Location: Room K2
Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier's long-term vision applies to its partnership philosophy. With €5.3Bn of revenue in 2023 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China. Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.
Location: Exhibit Hall Stage
The biotech industry has faced a 60% reduction in clinical trial initiations in 2024 compared to previous years. Despite some recovery, R&D funding is still below 2020/21 levels, and the complexity and costs of R&D continue to rise. Join this session to gain evidence-based insights and hear from leading women in biotech as they:
- Comment on the current macro environmental challenges impacting clinical development
- Discuss innovative strategies to overcome these hurdles
- Share their perspective on how EU biotech organizations can thrive amidst these challenges
Location: Exhibit Hall Stage
We look at how global events, deal making, and regulatory and tech advancements are determining the factors driving or squeezing production, while also finding time to focus on developments within a key area of the industry.
Location: Room K11
From the get-go, start-up and pre-clinical stage biopharmaceutical companies rightfully prioritize the scientific foundation of their invention, then swiftly transitioning towards Clinical Development. The priority is often reserved for securing fast-track, accelerated development pathways and expediting entry into first-in-human studies. Undoubtedly, Clinical Development stands as the key in the drug Information Classification: General development journey, commanding utmost attention: it is the highest risk, highest value creation, highest cost, most challenging, and highly regulated and monitored by Regulators Agencies. However, this pursuit of clinical milestones frequently results in the oversight of Chemistry, Manufacturing, and Controls (CMC) Development. Such neglect stems from underestimating the scope, complexity, timelines, cost, and impact of CMC Development - a prerequisite and indispensable precursor to any Toxicology and Clinical Development. This presentation will cover how to fully integrate CMC Development into the product development lifecycle and how pursuing excellence in CMC development will allow start-up and pre-clinical stage biopharmaceutical companies to realize substantial value.
Location: Exhibit Hall Stage
Join Dr. Michael May, a visionary leader in regenerative medicine, as he explores the vibrant landscape of Canada’s life sciences ecosystem with a special focus on AI and regenerative medicine. This session will showcase Canada’s cutting-edge advancements in cell and gene therapy, powered by its world-renowned AI capabilities and collaborative research and innovation culture.
Dr. May will highlight the pivotal role that CCRM plays in advancing regenerative medicine and catalyzing investment in breakthrough therapies. He will also discuss how AI is revolutionizing drug discovery, diagnostics, and personalized medicine in Canada. Attendees will hear first-hand how Canada’s research institutions, biotech companies, and innovators are collaborating to deliver life-changing therapies and positioning Canada as a global leader in life sciences.
Highlights:
- Gain insights into Canada’s latest innovations in advanced therapy and how they are reshaping healthcare.
- Learn about Canada’s thriving life sciences ecosystem and its unique ability to integrate world-class research, government support, and private-sector collaboration.
- Explore investment opportunities in Canada, including access to cutting-edge technologies, talent, and favorable incentives for businesses looking to expand or invest in the country.
- Hear success stories from companies and investors who have leveraged Canada’s resources to accelerate their growth in the life sciences industry.
This session is a must-attend for companies, investors, and innovators seeking to understand Canada’s competitive edge in life sciences and how they can capitalize on emerging opportunities in AI and regenerative medicine.
Location: Exhibit Hall Stage
This session will explore opportunities for biotech companies to develop and implement Advanced Therapy Medicinal Products (ATMPs) across Europe. Leading experts from key European hubs will discuss their collaborative efforts to enhance the visibility of European ATMP innovation and attract increased funding. By sharing insights and best practices, the session aims to foster a unified approach to addressing challenges in ATMP development, including clinical, financial, and workforce training issues. Attendees will gain a comprehensive understanding of the current landscape and future directions for advancing ATMP development in Europe.
Location: K18
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Location: K18
Spirea is a Cambridge University spin-out advancing a pipeline of Antibody Drug Conjugates (ADCs) with a lead programme targeting a tumour marker over-expressed in a number of cancers including triple-negative breast cancer. Spirea's ADCs incorporate a proprietary linker-payload technology which enables the incorporation of diverse drug payloads at drug-to-antibody ratios > 16. This provides for extremely high ADC design and payload flexibility and wide therapeutic index in cancer/oncology. Spirea is interested in collaborating with biotech and pharma companies to incorporate its high drug loading Antibody Drug Conjugate linker technology into new or pre-existing drug programmes.
Location: K18
Etnova Therapeutics Corp. has been conducting research and development on synthetic drug-based anticancer therapies since its founding in 2022. The company currently consists of 13 members, including 3 PhD-level researchers and 7 Master’s-level researchers. All researchers in the company are equipped with the expertise to handle the entire drug discovery process, from identifying new drug libraries, synthesis development, and efficacy evaluation to mechanism of action studies. Guided by the slogan 'A new era of therapeutic advances,' all members are united in striving towards the same goal. Here are the major events in the company's history: • August 2020: Company founded • October 2020: Secured angel investment • March 2022: Secured Series A investment • August 2023: IND approval for Phase 1 clinical trial of major pipeline ETN101 in Korea MFDS • February 2024: First patient enrolled in Phase 1 clinical trial of ETN101 in Korea The key pipeline under development is an oral anticancer drug, ETN101. In August 2023, it received IND approval for Phase 1 clinical trials in Korea, and the trials are now ongoing at four institutions nationwide. As of August 2024, Cohort 3 of the trial is currently in progress. In relation to the above, various indications are being expanded, and 8 national grant projects have been completed or are currently being carried out. As for intellectual property rights, 13 patents have been applied for and registered both domestically and internationally. Etnova Therapeutics completed the Series A investment in 2022 and Bridge investment in 2024, with plans for Series B in 2025. Additionally, we are considering SI/FI investment or licensing out for partnering opportunities. By expanding our pipeline and business internationally, we are strengthening our research capabilities and developing additional platform technologies. Etnova Therapeutics will usher in a new era of therapeutic development with a powerful leap forward.
Location: K18
Tenboron is a clinical stage biopharmaceutical company developing superior boron carriers for Boron Neutron Capture Therapy (BNCT) of cancers. BNCT is biochemically targeted radiation therapy especially suitable for treatment of non-resectable or recurrent tumors in the head and neck region. BNCT relies on efficient delivery of boron-10 atoms to cancer cells. When low energy neutron radiation is applied, the boron will react inside the cancer cells destroying them but sparing the surrounding healthy cells. BNCT has many advantages over conventional radiotherapy, but the adoption of this treatment modality has been handicapped by suboptimal carriers and lack of neutron sources. This is now changing as the construction of several new accelerator-based neutron sources is ongoing globally.
Location: K18
Osmol is a clinical stage biopharma company developing a first-in-class preventative treatment for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a significant unmet need associated with microtubule-based chemotherapies such as taxanes, the most widely used breast cancer chemotherapy treatment. CIPN can be both debilitating and effect cancer treatment outcomes. There are no approved treatments for CIPN, leaving patients’ only option to reduce the dose or length of chemotherapy treatment. Osmol’s initial focus is in breast cancer where up to 80% of taxane treated patients develop CIPN and 50% have their dose or length of treatment adjusted. , CIPN is driven by the dysregulation of neuronal calcium sensor-1 (NCS1). Osmol is developing a first-in-class, patented drug (OSM-0205) to modulate NCS1 function to prevent neuronal damage caused by the off-target effects of chemotherapy. The FDA completed its review of Osmol’s IND, notifying Osmol that our Phase 1 clinical study may proceed. In vivo and in vitro data support the development and effectiveness of OSM-0205 including: characterization of mechanism of efficacy, validation in mouse models of CIPN, and in vivo demonstration of no effect on chemotherapy efficacy. In addition, a limited clinical experience supports the therapeutic hypothesis. Finally, in vivo data support the potential for efficacy in a follow-on indication, chemotherapy-induced cognitive impairment (CICI). Market research with breast cancer specialists at leading US cancer centers confirmed the significant need for effective CIPN treatment, to prevent CIPN and allow for optimal chemotherapy treatment. In this same market research, payers covering 100M lives in the US confirmed the need for a preventative treatment and would reimburse it. Based on this market research, OSM-0205 peak sales for taxane-treated patients alone is projected to exceed $1.2B.
Location: K12
Founded in December 2020, HanchorBio is a clinical-stage biotech company with footprint spanning across multiple regions (USA, CHN, TWN). We specialize in developing novel, multi-targeting biomedicines through our “Fc-Based Designer Biologics” (FBDB) and “Shielded Designer ImmunoCytokine” (SDIC) platforms. Using proprietary protein engineering techniques, we have obtained an innate immunity engager (HCB101) that exhibits superior in vivo efficacy and marked safety profiles. These were fully demonstrated through in vivo efficacy testing of over 20 cancer models and two monkey toxicology studies. HCB101 is currently going through Phase I clinical trials. Our SDIC cytokine platform represents the most advanced version of guided immunocytokines that comprise all the desirable attributes such as superior safety features, outstanding in-vivo efficacy, favorable thermostability, and extended serum half-life. We have multiple SDIC programs in progress concurrently, covering indications in oncology and autoimmune diseases. As a spin-off from Henlius, HanchorBio’s colleagues possess a wide range of expertise and have over 10 years of experience in discovery research. We also recruit excellent scientists worldwide to achieve more diverse capabilities of innovation. This includes operations of an in-house animal facility with over 100 cancer models for in vivo testing. In addition, we have established process development (PD) capability to manage various aspects of upstream, downstream, analytical method developments, and up to 50L GLP toxicology material preparation. Due to this highly efficient, streamlined operation, we are able to advance pipeline programs in a rapid pace, obtaining our first IND clearance from the US FDA in 2.3 years since the company’s inception. Our ultimate goal is to overcome the limitations of the current checkpoint inhibitor approaches and lead the immune-based therapies into a new dimension.
Location: K12
Txinno Bioscience Inc. established in September 2020 with a vision to give hope and happiness to cancer patients and their family. Main Business Area is a dedicated company developing novel small molecule drugs for targeted therapy and immunotherapy to treat cancer patients. Txinno Bioscience is exclusively focused on developing innovative, small molecule anti-cancer drug candidates. We have 6 assets of various stages, among those, ENPP1 and ULK1 inhibitor are our representative pipelines. Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue. The first one is defined as tumor-intrinsic factors which are either genes or signaling pathways of tumor cells to directly control tumor cell proliferation or survival. Corresponding assets are ULK1 inhibitor, ‘Target S’ inhibitor, ‘Target I’ inhibitor and ‘Target Y’ inhibitor related to RAS signaling pathway. The other one is defined as tumor-extrinsic factors which are various signaling pathways operating in stromal cells other than tumor cells and promoting cancer cells to survive. Corresponding assets are ENPP1 inhibitor and ‘Target Z’ inhibitor controlling STING signaling pathway. In Txinno Bioscience, we developed two platform technologies to address these issues and facilitate our drug development process. 1) TxLFinder™ that can cultivate cancer cell spheroid and immune cells from PBMC in separate compartments of microplate wells. With immune cells appropriately stained for detection, the effect of drug treatment on infiltration of immune cells toward the spheroid can be measured. 2) TxTQuantifier™ is a co-culture system that are composed of spheroid from cancer cell line, isolated human immune cells, cancer-associated fibroblast, adipocytes and fabricated extracellular matrix to closely mimic actual human TME.
Location: K12
Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.
Location: K12
Accession Therapeutics is developing a proprietary pipeline of highly targeted immuno-oncology products with a range of therapeutic payloads. The ideal immunotherapy is highly specific to a tumour, broad in action to kill all cancer cell variants, and potent in activating the full immune system arsenal locally.
Location: Room K12
VacV is a cancer immunotherapy company developing viral-based therapies for cancer. Our versatile technology uses a novel oncolytic Vaccinia virus and is designed to create efficacious and safe treatments. Our promising pipeline of easy-to-administer treatments includes features that offer significant advantages compared to existing treatment options.
Location: Exhibit Hall Stage
Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.
Take a moment to exhale and move your body.
Calm your mind and feel the difference.
These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.
Open to all, without prerequisites.
Standing exercises only.
Sustainability Focus Area: Social Responsibility
Location: Room K1
Gain insights from leading pharma and venture investors on navigating the dealmaking landscape and standing out in the current climate. Discover strategies, trends, and key considerations for successful partnerships. Join this session to learn how to thrive in today's competitive environment and drive impactful collaborations.
Location: Room K1
Explore why AI is not just a trend but a transformative force shaping the future of healthcare and biopharma. Gain insights into its profound implications for research, development, and patient care.
Location: Room K1
Hear how AI algorithms are reshaping the landscape, accelerating the identification and development of novel therapeutics. Learn from industry experts about the latest advancements, challenges, and promising opportunities in this frontier of innovation.
Location: Room K1
Explore how AI-driven technologies are revolutionizing medical diagnostics, enhancing accuracy, efficiency, and patient outcomes. Gain valuable insights from experts on the latest developments, challenges, and future prospects in leveraging AI for diagnostic purposes.
Location: Exhibit Hall Stage
Explore the transformative impact of evolving pharmaceutical legislation on investor and company strategies within the life science ecosystem. Delve into the intricate interplay between regulatory changes, market dynamics, and strategic decision-making, as industry experts navigate the path forward amidst shifting landscapes and emerging opportunities.
Location: Exhibit Hall Stage
Join us for a fireside chat where experts assess the impact of US policies on the European life sciences ecosystem. Delve into the regulatory landscape, market dynamics, and strategic implications, exploring how transatlantic influences shape the future of biopharma innovation and collaboration.
Location: Room K2
We are a pharmaceutical company committed to research and development of medicines for patients around the world.
Location: Exhibit Hall Stage
This session will explore the transformative potential of intratumoral therapies, including local immune activators, oncolytic viruses and radioenhancers, in revolutionizing cancer treatment. As these novel treatments face unique challenges in drug delivery and clinical adoption, the role of venture capital investment becomes critical. Collaboration with small and medium-sized enterprises is essential to advance innovation, overcome barriers, and accelerate the development of intratumoral therapies. This discussion will emphasise how strategic investments and collaborations have been a springboard to drive growth in this emerging field and unlock the potential to transform the standard of care for cancer patients.
Location: Exhibit Hall Stage
Precision medicine represents a paradigm shift in healthcare, moving from a one-size-fits-all approach to personalized treatments based on an individual's genetic, environmental, and lifestyle factors. This session will explore the prospects of precision medicine, highlighting the technological, regulatory, and implementation challenges that must be overcome to integrate these advancements into the routine healthcare setting.
Location: Room K2
Big pharma’s ADC land grab has driven a multi-billion-dollar dealmaking frenzy. This session explains what the excitement is all about, providing insights into the current ADC landscape, latest innovations and challenges facing ADC development. Hear perspectives on the future of ADCs and their potential the reshape the paradigm of precision medicine.
Location: Room K2
Explore the burgeoning radioligand therapy landscape, with its multiple innovation areas and lucrative partnerships. Delve into the unique advantages of targeted radiotherapies, recent deals, and uncover the strategic opportunities that lie ahead.
Location: Room K2
Delve into the groundbreaking potential of cell and gene therapy and it’s potential to reshape healthcare as we know it. Explore the transformative impact of these therapies on disease treatment and prevention, challenging conventional medical paradigms. Discover how these innovative modalities are rewriting the rules of healthcare for a brighter future.
Location: Room K2
This session delves into the future of cardiometabolic therapy. As the buzz around GLP-1 receptor agonist-based drugs stabilises, the sector is already on the lookout for novel cardiometabolic treatment modalities. Dive into the collaborations focusing on cardiometabolic therapies, the implications and partnering strategies, in the evolving landscape of cardiometabolic care.
Location: Exhibit Hall Stage
The upcoming EHDS2 regulation, set to replace national laws that control healthcare data usage for research within the EU, aims to standardize cross-border access to healthcare data across the EU for both academic and commercial purposes. Accessing data remains a complex process due to GDPR legislation, involving multiple steps such as data availability queries, processing data access applications, and releasing pseudonymized data for Secure Processing Environments (SPE), federated data analysis or as anonymised format.
For data sources, this regulation requires providing data descriptions to the HealthData@EU portal, enabling researchers to find suitable data sources for their projects, as well as to reply data queries. As data sources become more accessible, the volume of data availability and data access applications is expected to increase significantly. Therefore, it is crucial to automate and optimize current, often manual, processes to meet the EHDS-defined time limits for responses and to keep track of work hours and other resources used in project level.
BC Platforms has developed various AI-enhanced software tools to support data sources, such as university hospitals and National Contact Points, in complying with the forthcoming EHDS requirements e.g. for meta data descriptions and data quality labelling, complex feasibility queries, data access application and approval handling, data anonymisation and data release to SPEs. For researchers and AI model developers, BC Platforms offers advanced data analysis software operating within a Secure Processing Environment (SPE), capable of tracking hardware or cloud costs by project.
BC Platforms collaborates with major healthcare data integrator companies to deliver solutions ranging from individual hospital implementations to national-scale systems.
Location: Exhibit Hall Stage
In the European Union (EU), medicines are authorized centrally, but reimbursement is carried out at the national level: the EU member states conduct national assessment procedures for this purpose, known as health technology assessments (HTAs). Harmonization of these procedures is one of the most important innovations in the regulatory framework for medicines in Europe. From January 2025, a common clinical assessment will come into force in the EU. This will be introduced gradually, starting with cancer medicines (including orphan oncology drugs) and ATMPs. A whole series of important EU regulations came into force in 2024. Currently, national regulations are being adapted to the new European procedure in the EU member states. And now, in the fall of 2024, many details regarding the implementation and execution of the new procedure are clarified. This panel will discuss how small and large biopharmaceutical companies need to adapt to the new procedure to reach Europe’s patients quickly and successfully with their innovative therapies.
Location: Room K11
We will address the critical challenge of translating academic research into practical applications that benefit patients across Europe. Experts from various fields—including healthcare, policy-making, and patient advocacy—will discuss innovative strategies to enhance collaboration between researchers and healthcare practitioners. Key topics will include the importance of patient-centered research, effective communication of scientific findings, and the role of technology in facilitating access to information. Panelists will share current initiatives and explore frameworks for fostering partnerships that ensure research outcomes are effectively implemented in clinical settings.
Location: Room K11
The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live competition will give a group of hand selected startups the opportunity to pitch in front of the BIO-Europe audience. A panel of esteemed judges will evaluate the pitches and select the winners.
Startup Finalists: *Presenting in order
Harmonic Discovery: Oncology
Kadence Bio: Neurology & Rare Diseases
Loma Therapeutics: Oncology
Nia Health GmbH: Digital Health
Sarcomatrix Therapeutics Corp.: Neurology & Rare Diseases
StemSight: Cell & Gene
Theratrame S.A.: Oncology
V4CURE: Neurology & Rare Diseases
Location: Room K18
TargTex is a pioneering biotechnology company dedicated to the development of innovative therapeutic approaches for life-threatening diseases. Our primary focus is on oncology and cardiovascular indications, with a special emphasis on exploring the calcium channel TRPV2 as a novel therapeutic target. Our lead candidate is a groundbreaking treatment for Glioblastoma (GBM), the most common and aggressive type of primary brain cancer. GBM is one of the most challenging cancers to treat due to its heterogeneity, highly invasive nature and resistance to conventional therapies. Our lead treatment aims to address these challenges through a precision delivery approach, based on proprietary hydrogel nano-formulation carrying a small molecule targeting the TRPV2 calcium channel. With a potential seamless integration as part of the standard of care, preclinical studies have demonstrated that the lead product can eradicate the tumour, without signs of toxicity and systemic off-target exposure. The pre-clinical data and clinical development plans were validated at a pre-IND meeting with the FDA, providing a clear regulatory path for development. The company already engaged top tier clinical sites in Spain, France and USA to establish a phase 1/2a clinical trial in recurrent patients. Beyond Glioblastoma, TRPV2 has been implicated in cancer cell proliferation, migration, and survival and presents as a promising target for a range of oncological conditions. In addition, TRPV2 is involved in cardiac muscle function and its role has been clinically explored in cardiovascular indications such as heart failure. With a strong focus on TRPV2 and a promising lead candidate for Glioblastoma, our R&D efforts are focused on leveraging TRPV2 allosteric modulation to create a pipeline of therapies that address high unmet medical needs, aiming to develop first-in-class new medicines that make a significant impact on patients' lives and global health.
Location: Room K18
Abion | Leading the Future of Oncology: First-in-Class Claudin-3 Targeting Antibody and Our Pan-Cancer Antibody-Cytokine Fusion Platform Beyond ADC
In oncology, ABION is advancing ABN202, an innovative antibody-cytokine fusion protein utilizing Interferon-β mutein technology, designed to provide exceptional anti-tumor efficacy. This novel platform not only enhances treatment options beyond traditional ADCs but also has the potential to synergize effectively with immune checkpoint inhibitors, establishing it as a versatile solution for advanced cancer therapies. Following this, ABN501, a first-in-class anti-Claudin-3 monoclonal antibody, is being developed to provide therapeutic options for various cancers, as the Claudin family has recently gained focus and popularity.
Location: Room K18
We are a biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology. With capabilities from lab to patient, including a decentralized cell therapy manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders.
Location: Room K18
RS Oncology is a private clinical stage biotechnology company based in Cambridge, MA with a mission to leverage new scientific discoveries to develop meaningful therapies against the most aggressive cancers. RSO’s therapeutic pipeline is focused on modulating mitochondrial pathways that drive diseases of oxidative stress, with a primary focus on cancer. Our lead program, RSO-021, is a novel first-in-class, first-in-human small molecule that irreversibly binds mitochondrial peroxiredoxin 3 (PRX3) through covalent adduction of the active site. PRX3 is a new oncology target shown in preclinical models to support tumor cell escape from apoptosis, ferroptosis and promote proliferation. RSO-021 recently met its primary endpoint of safety and tolerability in Phase 1 testing (and showed efficacy) and is currently being evaluated in a multi-arm dose expansion Phase 2 clinical trial in the UK. In translational studies RSO-021 reduces the expression of pro- metastatic epithelial to mesenchymal (EMT) genes, induces apoptosis of tumor explants and alters the immune profile of the tumor microenvironment. In addition, RSO is developing a pipeline of systemic PRX3 inhibitors currently in the IND enabling stage.
Location: Room K18
OncoLize: “Treating Tumors from the Inside” - OncoLize (Leiden, NL) develops injectable drug depots for localized, intra-tumoral injections. Based on successful pre-clinical data in Lung tumors and PDAC, and with clear cost-effective scale-up potential, the company is preparing its IMPD/IND and CT Phase I/II for pancreatic cancer and other indications. - The products are delivered into solid tumors using image guided endoscopes, catheters, and fine injection needles. Delivering generic chemo or novel drugs in this localized manner offers precision: a) 10-100x higher concentration at target with b) much smaller total doses and c) up to 1000x lower drug levels outside the tumor… Pre-clincial studies in established Pancreatic tumor and Lung tumor models have shown spectacular tumor growth inhibition with evidence of immune activation from 'cold' to 'hot'. Current work is focused on no0n-clinical safety and tox studies and scale-up/CMC to clinical grader products. 3. As 90% of all cancers are solid tumors, 70% of all tumors are diagnosed before metastasis, and the mean age of patients is 66 years of age when first diagnosed, local and sustained release offers a powerful proposition to treat patients with better outcome, far less side effects and making it Triple A: Affordable and Accessible for All. 4. OncoLize features a highly experienced founders’ team which closed a Seed A round of €1,6 million, and is preparing a Seed B round of €1 million. We aim to raise a Series A €10+ mln by mid 2025 to achieve CT phase I/II studies in up to 3 indications with a pipeline of multiple product market combinations, scale-up of products for clinical trials and early commercialization potential. 5. Patents from 2017 have been granted in USA, China and Japan, with EU in final stages and more to come. 6. The company also seeks to partner for impact in less privileged communities, so collaboration with NGO’s and impact investors is as much welcomed as VC-backed funding.
Location: Room K18
Cleara Biotech B.V. (www.clearabiotech.com) develops therapies diseases caused by scarred cells, with a focus on late-stage, metastatic cancer. Based on a patented MoA, Cleara nominated a development candidate, CL04183. CL04183 is especially potent and selective against biomarker-positive types of cancer in mouse models and 3D cancer patient-derived organoids. Cleara is within 12-18 months form the clinic, with IMPD -enabling GLP-TOX and CMC funded and scheduled for completion in Q1-2 2025. Scarred cancer cells not only continue to divide, but are highly invasive, and generally more resistant to treatment. Cleara identified these cells to show elevated levels of the proteins PML and a phosphorylated form of the guardian protein p53. Through its cell-penetrating peptide (CPP) platform technology Cleara integrated cycles of structural, biochemical and cellular discovery to ultimately nominate CL04183. CL04183 is unique in that it is optimized around binding this (phosphorylated) complex and triggering transcription-independent apoptosis. Importantly, CL04183 is also highly effective when p53 is mutated, as is the case in many metastatic types of cancer. Cleara is based in Utrecht, the Netherlands and closely tied to the University Medical Center, giving it wide access to research, clinical data and patients. It has established and highly experienced Management, Board and Development teams in the Netherlands, Germany, Switzerland and the US. Cleara is already funded by Apollo Health Ventures (www.apollo.vc) which is the founding VC, as well as other life science focused groups, including Curie Capital (www.curiecapital.nl). Moreover, following stringent due diligence, Cleara is supported by public funds from the Regional Development Fund and the Dutch Government. All of these plan to participate in the Series A financing. For Ph1 and Ph2 trials against scarring-positive Colon, breast and ovarian cancer, Cleara is currently looking for Series-A financing.
Location: Room K18
BioInvent International AB (publ) ( Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1b and 2a trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
Location: Room K18
Ziphius, founded in 2019, is a Belgian-based pharmaceutical company with a mission to reduce the global impact of infectious and rare genetic diseases. Through its innovative Platform Technology utilizing self-amplifying RNA (saRNA), the company develops safe and effective biopharmaceuticals, including prophylactic vaccines and gene supplementation therapies. Located in New York, USA and Zwijnaarde, Belgium. Ziphius focuses on combining self-amplifying saRNA technologies with advanced lipid formulations for targeted delivery. Their primary emphasis lies in the preclinical and early clinical phases, addressing prophylactic vaccines and protein-enhancement therapies for rare genetic disorders. The team consist of complementary highly dedicated experts with a strong entrepreneurial, scientific, clinical, managerial and pharmaceutical background Ziphius focuses on two main areas: • Prophylactic Platform: In this domain, Ziphius aims to develop medicines for protecting individuals against commonly occurring infectious pathogens, including viruses and bacteria. The self-amplifying (sa) RNA technology involves an RNA backbone, a gene encoding a specific antigen/polypeptide/protein, and a lipid-rich envelope (lipid nanoparticles or LNP). Post-injection, this envelope fuses with the patient's cell membrane, releasing synthetic saRNA molecules into the cell. These molecules instruct cells to produce the encoded antigen/polypeptide/protein, triggering a robust and long-lasting immune response. Ziphius meticulously tests combinations of RNA backbones and lipid envelopes to select the optimal combination for developing saRNA-based vaccines. • Therapeutics : This department seeks therapies to alleviate symptoms and enhance the quality of life for patients. Utilizing saRNA technology with tailored delivery vehicles. Ziphius aims to reduce side effects and achieve targeted delivery. The technology offers the potential for increased protein production and persistent expression.
Location: K12
CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments. Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties. CombiGene has a team of very knowledgeable and experienced professionals, as well as solid, longstanding experience from the international pharma industry and the biotech arena, together with a thorough knowledge of different aspects of gene therapy. This combination of experience and expertise allows CombiGene, together with a network of selected external partners who complement CombiGene’s internal expertise, to conduct ground-breaking gene-therapeutic development very effectively.
Location: K12
Neuracle Genetics, a clinical stage biotechnology company, is committed to improving patients' lives by harnessing the curative potential of gene therapy. We are developing innovative AAV gene therapy product candidates to treat retinal and neurological diseases with significant unmet needs. Leveraging our proprietary technologies, our product candidates are designed and optimized for safety and efficacy, with the goal of providing broader access to patients.
Location: K12
Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. .
Location: K12
Cellevate AB is a biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture systems for cell and gene therapy and novel vaccines. Our 5-year goal is to transform upstream bioprocessing with our sustainable ground-breaking cellulose based nanofiber microcarriers, produced by proprietary methods for industrial biomanufacturing of novel biotherapies. We currently employ 15 FTEs at our production facility in Lund, Sweden. In 2024/2025 we will establish a US office & expand in other European countries with large numbers of CDMOs and biopharma bioproduction such as Germany, Austria, Switzerland, Belgium Netherlands, France and UK. We estimate to grow to 60 FTEs in 2026. With validations performed, Cellevate is strategically positioned to advance to its next phase of growth and commercialization. The first product portfolio, Cellevat3dTM nanofiber microcarriers has a global commercial launch at this event, BIO-Europe, November, 2024. The product portfolio is designed to improve yield and productivity of viral vectors production in gene therapy applications, thereby increasing patient accessibility to these costly therapeutics. Cellevat3dTM nanofiber microcarriers provide unparalleled surface area for cell culturing, mimic accurately the human body’s extracellular environment and are scalable from R&D to commercial manufacturing.
Location: K12
TiCARos is a clinical-stage biotech developing next-generation CAR-T cell therapies aimed at treating hematologic malignancies and solid tumors. Our foundation lies in our three proprietary platforms that drive innovation and improve therapeutic outcomes. Central to our approach is the CLIP (CLamping-based Immunological Potentiation) CAR platform, a CAR backbone modification technology that enhances the formation and stability of the immunological synapse. This platform significantly boosts the longevity and efficacy of CAR-T cell therapies, allowing for more effective engagement and elimination of cancer cells. In addition to CLIP, TiCARos is pioneering other transformative technologies, including the Converter CAR and Switchable CAR platforms. Converter CAR technology is designed to amplify T-cell activation, thereby increasing the therapeutic potency and durability of CAR-T treatments. Switchable CAR technology provides precise control over CAR-T cell activity, allowing for real-time modulation of the immune response to enhance safety and reduce off-target effects. Together, these platforms offer a comprehensive approach to developing safer, more effective cancer therapies that can be tailored to meet the specific needs of different tumor types. TiCARos is led by a team of seasoned industry experts and scientific leaders who bring decades of experience in cell therapy and immunotherapy. Our Chief Technology Officer, Prof. Kyungho Choi, is a renowned expert in the field of immuno-oncology, with an extensive background in CAR-T cell research and development. Through strategic partnerships with leading research institutions and biotechnology companies, TiCARos is well-positioned to bring our next-generation CAR-T therapies to the forefront of the global oncology market.
Location: K12
Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech. Its first candidate, AURN001, is for the treatment of corneal edema secondary to corneal endothelial disease, and the first clinically validated cell therapy for corneal care, having already received regulatory approval in Japan. From a single donor, Aurion Biotech can reproduce enough fully differentiated corneal endothelial cells to treat up to 1,000 eyes. This allogeneic cell therapy does not require immune type matching, nor any form of gene editing. Consequently, company leadership believes AURN001 may become the first “mass market” allogeneic cell therapy. Aurion Biotech has completed enrollment and dosing of its Phase 1 / 2 clinical trial in the U.S. and Canada and hopes to have topline data available in early 2025. Recently, the U.S. F.D.A. granted both Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for AURN001. The Company believes these designations speak to the promise and potential of AURN001 to address a massive, global unmet need. Privately held, Aurion Biotech is backed by Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.
Location: K12
Mediphage, a Toronto-based biotechnology company, has developed a minimal and back-bone free, high-fidelity, linear covalently closed (LCC) DNA vectors, called ministring DNA (msDNA), which it produces through its proprietary, scalable E. coli-based manufacturing process. msDNA can be used as high-quality starting material in viral vector production (rAAV, lentivirus) and mRNA vaccines and therapeutics and as drug substance in gene therapy and gene editing for therapeutics development. Product differentiation of msDNA’s ‘Plug-and-play’ genetic medicine platform and its rapid, scalable production process has generated growing demand for msDNA evaluation across the therapeutics and biotools industry. Mediphage has a number of collaborations with pharma partners, biotech companies, CDMOs, and research organizations evaluating msDNA for various applications. Internally, Mediphage is developing redosable and durable non-viral gene therapy assets for liver, CNS, and ophthalmic disorders.
Location: Room K12
Affinia Therapeutics is pioneering a new class of rationally designed gene therapies to treat rare and prevalent diseases. The Affinia Rationally designed Therapeutics (ART) platform synergistically improves the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches
Location: Exhibit Hall Stage
Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.
Take a moment to exhale and move your body.
Calm your mind and feel the difference.
These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.
Open to all, without prerequisites.
Standing exercises only.
Sustainability Focus Area: Social Responsibility